• Case report of Guillena–Barre syndrome during pregnancy
To content

Case report of Guillena–Barre syndrome during pregnancy

HEALTH OF WOMAN. 2017.10(126):85–89; doi 10.15574/HW.2017.126.85

Makarenko M. V., Govsieiev D. O., Sokol I. V., Berestovoy V. O., Vorona R. M.
A.A. Bogomolets National Medical University, Kiev

In this case report we describe the case of Guillain-Barrй syndrome during the third trimester of pregnancy. Clinical manifestations of the disease progressed extremely fast, and condition of the pregnant woman determined as hard. After cesarean section woman’s condition did not improved and decided to undergo treatment with intravenous immunoglobulins. After treatment status of nervous system gradually improved. At 49 the day of admission to the hospital and the course of intravenous immunoglobulin, woman discharged home under the supervision of a neurologist and the gynecologist.
Key words: Guillain-Barre syndrome, intravenous immunoglobulins, multidisciplinary tactics of patients management.

REFERENCES

1. Makarenko MV, Hovsieiev DO, Berestovyi VO, Sokol IV, Vorona RM. 2017. Perynatalni aspekty imunokorektsii u vahitnykh z antyfosfolipidnym syndromom. Materialy «Plenumu Asotsiatsii akusheriv-hinekolohiv Ukrainy ta naukovo-praktychnoi konferentsii z mizhnarodnoiu uchastiu»: 29–30.

2. Makarenko MV, Hovsieiev DO, Berestovyi VO, Sokol IV, Vorona RM. 2017. Korektsiia imunnoho balansu u vahitnykh z antyfosfolipidnym syndromom. Materialy «Plenumu Asotsiatsii akusheriv-hinekolohiv Ukrainy ta naukovo-praktychnoi konferentsii z mizhnarodnoiu uchastiu»: 34–35.

3. Piradov MA. 2003. Sindrom Giyena–Barre. M. Inter-medika:240. 
4. Piradov MA. Suponeva NA. 2011. Sindrom Giyena-Barre: diagnostika i lecheniye. M. MEDpress-inform.
5. Suponeva NA. 2013. Klinicheskaya i diagnosticheskaya rol autoantitel k glikozidam perifericheskikh nervov: obzor literatury i sobstvennyye dannyye. Nervnomyshechn. bolezni (1):26–35. 
6. Suponeva NA. Piradov MA. Grishina DA. Molchalova EG. 2014. Effektivnost patogeneticheskoy terapii pri sindrome Giyena–Barre. Effektivn. farmakoterap. (58):12–20.
7. Suponeva NA. Piradov MA. Nikitin SS i dr. 2013. Patogeneticheskaya i prognosticheskaya rol autoantitel k glikozidam perifericheskikh nervov pri sindrome Giyena–Barre. Annaly klinicheskoy i eksperimentalnoy nevrologii 7;1:4–11.

8. Balogun RA, Kaplan A, Ward DM et al. 2010. Clinical application of therapeutic apheresis. J. Clin. Apheresis. 25:250–264. https://doi.org/10.1002/jca.20250; https://doi.org/10.1002/jca.20249; PMid:20806279

9. Burns TM. 2008. Guillain–Barré syndrome. Semin. Neurol. 28(2):152–167. https://doi.org/10.1055/s-2008-1062261; PMid:18351518

10. Chan LY, Tsue MH, Leung TN. 2004. Guillain–Barre syndrome in pregnancy. Acta obstetrician et gynecologica Scandinavica. 83:319–325. https://doi.org/10.1080/j.0001-6349.2004.0473.x; https://doi.org/10.1111/j.0001-6349.2004.0473.x

11. Chio A, Cocito D, Leone M et al. 2003. Guillain– Barré syndrome: a prospective, population-based incidence and outcome survey. Neurol. 60:1146–1150. https://doi.org/10.1212/01.WNL.0000055091.96905.D0

12. Clarence C. Tam and et al. 2006. J. Infect. Dis. 194:95–97. https://doi.org/10.1086/504294; PMid:16741887

13. Dada MA, Kaplan AA. 2004. Plasmapheresis treatment in Guillain–Barre syndrome: potential benefit over IVIg in patients with axonal involvement. Ther. Apher. Dial. 8:409–412. https://doi.org/10.1111/j.1526-0968.2004.00183.x; PMid:15663537

14. Donofrio PD. 2003. Immunotherapy of idiopathic inflammatory neuropathies. Muscle Nerve. 28:273–292. https://doi.org/10.1002/mus.10402; PMid:12929187

15. Ganovi V, Granieri E. 2001. Epidemiology of the Guillian – Barre syndrome. Curr. Opion. Neurology. 14:605–613. https://doi.org/10.1097/00019052-200110000-00009

16. Hughes RA, Cornblath DR. 2005. Gullain-Barré syndrome. Lancet. 366;9497:1653–1666. https://doi.org/10.1016/S0140-6736(05)67665-9

17. Hughes RA, Wijdiks EF, Barohn R et al. 2005. Quality Standarts Subcommitte of the American Academy of Neurology. Practice parameter: immunotherapy for Guillain–Barré syndrome: report of the Quality Standarts Subcommitte of the American Academy of Neurology. Neurol. 61:736–740. https://doi.org/10.1212/WNL.61.6.736

18. Inamdar SA, Inamdar AH, Chaudhary R et al. 2013. Successful maternal and fetal outcome of Guillain–Barre syndrome complicating pregnancy: case report. Int. J. Reprod. Contracept obstet Gynecol. 2;3:478–479. https://doi.org/10.5455/2320-1770.ijrcog20130952

19. Kaynar L, Altuntas F, Aydogdu I et al. 2008. Therapeutic plasma exchange in patients with neurologic diseases: retrospective multicenter study. Transfus. Apher. Sci. 38:109–115. https://doi.org/10.1016/j.transci.2007.11.002; PMid:18331814

20. Lannello S. Guillain–Barre syndrome: pathological, clinical, and therapeutical aspects / S. Iannello. – NewYork: Nova Biomedical Books. 2005:234.

21. Mc Grogan A, Madle GC, Seaman HE, de Vries CS. 2009. The epidemiology of Guillain–Barré syndrome worldwide. A systematic literature review. Neiroepidemiology. 32(2):150–160. https://doi.org/10.1159/000184748; PMid:19088488

22. Parry G.J., Steinberg J.S.. Guillain–Barre syndrome: from diagnosis to Parry, G.J. recovery. AAN Enterprises. 2007: 264. PMid:17596189

23. Szczepiorkowski ZM, Winters JL, Bandarenko N et al. 2010. Guidelines on the use of therapeutics apheresis in Clinical Practice-Evidence-Based Approach from the Apheresis Applications Committee of the American Society for Apheresis. J. Clin. Apheresis. 25:83. https://doi.org/10.1002/jca.20240; PMid:20568098

24. Sejvar JJ, Baughman AL, Wise M et al. 2011. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 36;2:123–133. https://doi.org/10.1159/000324710; PMid:21422765 PMCid:PMC5703046

25. Seoud M, Naboulsi M, Khalil A et аl. 1999. Landry Guillain—Barre Strohl syndrome in pregnancy: use of high-dose intravenous immunoglobulin. Acta obstetrician et gynecologica Scandinavica. 78:912–918. https://doi.org/10.1080/j.1600-0412.1999.781014.x

26. Susuki K, Rasband MN, Tohyama K et al. 2007. AntiGM1 antibodies cause cjmplement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J. Neurosci. 27(15):3956–3967. https://doi.org/10.1523/JNEUROSCI.4401-06.2007; PMid:17428969

27. Van Doorn PA, Ruts L, Jacobs BC. 2008. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 7;10:939–950. https://doi.org/10.1016/S1474-4422(08)70215-1

28. Willison HJ. 2005. The immunobiology of Guillain–Barre syndromes. J. Peripher. Nerv. Syst. 10:1094–1112. https://doi.org/10.1111/j.1085-9489.2005.0010202.x; PMid:15958123

29. Yuki N. 2012. Guillain–Barré syndrome and antiganglioside antibodies a clinician-scientist’s jorney. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 88(7):299–326.

30. Yuki N, Hartung HP. 2012. Guillain- Barré syndrome. N. Engl. J. Med. 366;24:2294–2304. https://doi.org/10.1056/NEJMra1114525; PMid:22694000

31. Zafar MH, Naqash MM, Bhat TA et al. 2013. Guillain–Barre syndrome in pregnancy: an unusual case. J. Fam. Med. Primary Care. 2:90–91. https://doi.org/10.4103/2249-4863.109965; PMid:24479054 PMCid:PMC3894025